StifelStill a very healthy target from here. GLTA
Ahead of investor tour next week in Europe, Stifel’s Justin Keywood cut his ATS Corp. target to $58 from $60 with a “buy” rating. The average is $57.50. “We anticipate deep insight into autoinjector assembly lines for GLP-1 as the highest growth area, along with nuclear medicine and radio pharmaceutical technologies and processing/packaging for food products,” he said. “We also roll out new F2026 forecasts and adjust F2025 estimates as a transition year, from material EV headwinds, anticipated to comprise 22 per cent of sales vs. 31 per cent year-over-year. Our F2026 estimates assumes EV declines moderate, as OEM ordering inertia, heading into the U.S. election, could subside. We expect continued strength in Life Sciences, including from record FQ1 backlog. M&A continues to be part of our thesis and could materially change forecasts.”